Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission

L. Trentin, G. Pizzolo, C. Feruglio, R. Zambello, M. Masciarelli, P. Bulian, C. Agostini, F. Vinante, R. Zanotti, G. Semenzato

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In the current study, we investigated the cytotoxic ability of peripheral blood mononuclear cells (PBMC) recovered from patients with acute nonlymphoblastic leukemia (ANLL) in complete remission (CR) against natural killer (NK)-sensitive, NK-resistant, autologous and allogeneic leukemic target cells taken at diagnosis. Our purpose was to define the role played by cytotoxic mechanisms in the control of leukemic cell growth in ANLL. Experiments were carried out at resting conditions and after in vitro activation with recombinant interleukin-2 (rIL-2) and anti-CD3 monoclonal antibody (moAb). At resting conditions, PBMC recovered from ANLL patients displayed a NK function that was not significantly different from controls (mean ± standard error of the mean [SEM]: 21.9% ± 3.9% versus control values of 27.5% ± 2.9%; the P value was not significant [NS]), but they were unable to show cytoxic activity against autologous and allogeneic leukemic cells. After in vitro boosting with rIL-2, PBMC were able to generate lymphokine activated killer (LAK) cells, as demonstrated by an increased killing of NK-resistant Daudi targets (16.3% ± 2.7%). Although LAK activity was quantitatively lower than in control subjects (mean ± SEM: 16.3% ± 2.7% versus control values of 79.8% ± 3.1%, P <0.001), it still exerted a cytotoxic effect against autologous and allogeneic leukemic cells. Similar results were obtained when anti-CD3 moAb was used as a stimulus in vitro. Our data suggest that nonspecific cytotoxic cells may be triggered to exert an in vitro cytotoxic effect on leukemic cells, which could possibly play a key role in vivo in the control of leukemic cell growth regulation.

Original languageEnglish
Pages (from-to)667-672
Number of pages6
JournalCancer
Volume64
Issue number3
Publication statusPublished - 1989

Fingerprint

Acute Myeloid Leukemia
Blood Cells
Interleukin-2
Monoclonal Antibodies
Lymphokine-Activated Killer Cells
Lymphokines
Growth
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trentin, L., Pizzolo, G., Feruglio, C., Zambello, R., Masciarelli, M., Bulian, P., ... Semenzato, G. (1989). Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer, 64(3), 667-672.

Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. / Trentin, L.; Pizzolo, G.; Feruglio, C.; Zambello, R.; Masciarelli, M.; Bulian, P.; Agostini, C.; Vinante, F.; Zanotti, R.; Semenzato, G.

In: Cancer, Vol. 64, No. 3, 1989, p. 667-672.

Research output: Contribution to journalArticle

Trentin, L, Pizzolo, G, Feruglio, C, Zambello, R, Masciarelli, M, Bulian, P, Agostini, C, Vinante, F, Zanotti, R & Semenzato, G 1989, 'Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission', Cancer, vol. 64, no. 3, pp. 667-672.
Trentin L, Pizzolo G, Feruglio C, Zambello R, Masciarelli M, Bulian P et al. Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer. 1989;64(3):667-672.
Trentin, L. ; Pizzolo, G. ; Feruglio, C. ; Zambello, R. ; Masciarelli, M. ; Bulian, P. ; Agostini, C. ; Vinante, F. ; Zanotti, R. ; Semenzato, G. / Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. In: Cancer. 1989 ; Vol. 64, No. 3. pp. 667-672.
@article{02208c945a1a4e93bd0e128da1c96e66,
title = "Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission",
abstract = "In the current study, we investigated the cytotoxic ability of peripheral blood mononuclear cells (PBMC) recovered from patients with acute nonlymphoblastic leukemia (ANLL) in complete remission (CR) against natural killer (NK)-sensitive, NK-resistant, autologous and allogeneic leukemic target cells taken at diagnosis. Our purpose was to define the role played by cytotoxic mechanisms in the control of leukemic cell growth in ANLL. Experiments were carried out at resting conditions and after in vitro activation with recombinant interleukin-2 (rIL-2) and anti-CD3 monoclonal antibody (moAb). At resting conditions, PBMC recovered from ANLL patients displayed a NK function that was not significantly different from controls (mean ± standard error of the mean [SEM]: 21.9{\%} ± 3.9{\%} versus control values of 27.5{\%} ± 2.9{\%}; the P value was not significant [NS]), but they were unable to show cytoxic activity against autologous and allogeneic leukemic cells. After in vitro boosting with rIL-2, PBMC were able to generate lymphokine activated killer (LAK) cells, as demonstrated by an increased killing of NK-resistant Daudi targets (16.3{\%} ± 2.7{\%}). Although LAK activity was quantitatively lower than in control subjects (mean ± SEM: 16.3{\%} ± 2.7{\%} versus control values of 79.8{\%} ± 3.1{\%}, P <0.001), it still exerted a cytotoxic effect against autologous and allogeneic leukemic cells. Similar results were obtained when anti-CD3 moAb was used as a stimulus in vitro. Our data suggest that nonspecific cytotoxic cells may be triggered to exert an in vitro cytotoxic effect on leukemic cells, which could possibly play a key role in vivo in the control of leukemic cell growth regulation.",
author = "L. Trentin and G. Pizzolo and C. Feruglio and R. Zambello and M. Masciarelli and P. Bulian and C. Agostini and F. Vinante and R. Zanotti and G. Semenzato",
year = "1989",
language = "English",
volume = "64",
pages = "667--672",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission

AU - Trentin, L.

AU - Pizzolo, G.

AU - Feruglio, C.

AU - Zambello, R.

AU - Masciarelli, M.

AU - Bulian, P.

AU - Agostini, C.

AU - Vinante, F.

AU - Zanotti, R.

AU - Semenzato, G.

PY - 1989

Y1 - 1989

N2 - In the current study, we investigated the cytotoxic ability of peripheral blood mononuclear cells (PBMC) recovered from patients with acute nonlymphoblastic leukemia (ANLL) in complete remission (CR) against natural killer (NK)-sensitive, NK-resistant, autologous and allogeneic leukemic target cells taken at diagnosis. Our purpose was to define the role played by cytotoxic mechanisms in the control of leukemic cell growth in ANLL. Experiments were carried out at resting conditions and after in vitro activation with recombinant interleukin-2 (rIL-2) and anti-CD3 monoclonal antibody (moAb). At resting conditions, PBMC recovered from ANLL patients displayed a NK function that was not significantly different from controls (mean ± standard error of the mean [SEM]: 21.9% ± 3.9% versus control values of 27.5% ± 2.9%; the P value was not significant [NS]), but they were unable to show cytoxic activity against autologous and allogeneic leukemic cells. After in vitro boosting with rIL-2, PBMC were able to generate lymphokine activated killer (LAK) cells, as demonstrated by an increased killing of NK-resistant Daudi targets (16.3% ± 2.7%). Although LAK activity was quantitatively lower than in control subjects (mean ± SEM: 16.3% ± 2.7% versus control values of 79.8% ± 3.1%, P <0.001), it still exerted a cytotoxic effect against autologous and allogeneic leukemic cells. Similar results were obtained when anti-CD3 moAb was used as a stimulus in vitro. Our data suggest that nonspecific cytotoxic cells may be triggered to exert an in vitro cytotoxic effect on leukemic cells, which could possibly play a key role in vivo in the control of leukemic cell growth regulation.

AB - In the current study, we investigated the cytotoxic ability of peripheral blood mononuclear cells (PBMC) recovered from patients with acute nonlymphoblastic leukemia (ANLL) in complete remission (CR) against natural killer (NK)-sensitive, NK-resistant, autologous and allogeneic leukemic target cells taken at diagnosis. Our purpose was to define the role played by cytotoxic mechanisms in the control of leukemic cell growth in ANLL. Experiments were carried out at resting conditions and after in vitro activation with recombinant interleukin-2 (rIL-2) and anti-CD3 monoclonal antibody (moAb). At resting conditions, PBMC recovered from ANLL patients displayed a NK function that was not significantly different from controls (mean ± standard error of the mean [SEM]: 21.9% ± 3.9% versus control values of 27.5% ± 2.9%; the P value was not significant [NS]), but they were unable to show cytoxic activity against autologous and allogeneic leukemic cells. After in vitro boosting with rIL-2, PBMC were able to generate lymphokine activated killer (LAK) cells, as demonstrated by an increased killing of NK-resistant Daudi targets (16.3% ± 2.7%). Although LAK activity was quantitatively lower than in control subjects (mean ± SEM: 16.3% ± 2.7% versus control values of 79.8% ± 3.1%, P <0.001), it still exerted a cytotoxic effect against autologous and allogeneic leukemic cells. Similar results were obtained when anti-CD3 moAb was used as a stimulus in vitro. Our data suggest that nonspecific cytotoxic cells may be triggered to exert an in vitro cytotoxic effect on leukemic cells, which could possibly play a key role in vivo in the control of leukemic cell growth regulation.

UR - http://www.scopus.com/inward/record.url?scp=0024381153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024381153&partnerID=8YFLogxK

M3 - Article

C2 - 2787199

AN - SCOPUS:0024381153

VL - 64

SP - 667

EP - 672

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -